Date
|
Name
|
Institution
|
Seminar
|
| Dec. 19, 2001 |
Rafi Ahmed |
Emory University |
Immunological Memory: Lessons for vaccine development PLEASE Note: This talk will be in the Masur Auditorium (Building 10) as part of WALS (Wednesday) |
| Dec. 14, 2001 |
Jaap Goudsmit |
|
Vaccines that do not prevent HIV infection: the technical challenges, the individual consequences and the population effect. |
| Dec. 11, 2001 |
Marjorie Robert-Guroff |
NCI |
Immunogenicity and protective efficacy of adenovirus-recombinant vaccines for AIDS |
| Nov. 20, 2001 |
David Weiner |
University of Pennsylvania |
Improvements and complications of multicomponent DNA vaccines for HIV-1 |
| Nov. 13, 2001 |
Harriet Robinson |
Yerkes Primate Center and Emory University |
Working towards an AIDS Vaccine |
| Nov. 6, 2001 |
Steve Hoffman |
Celera, Inc. |
From Genomics to Proteomics to Vaccine: A 21st Century Challenge |
| Oct. 30, 2001 |
Hana Golding |
CBER/FDA |
Dissection of HIV-1 entry mechanism by neutralizing antibodies to gp41 fusion intermediate structures |
| Oct. 23, 2001 |
Francine McCutchan, Ph.D. |
Henry M. Jackson Foundation |
HIV Recombination and Vaccine Development |
| Oct. 16, 2001 |
Jeff Lifson |
NCI/Frederick |
Monkey Tales: Insights into AIDS Virus pathogenesis from studies of non-human primates |
| Oct. 9, 2001 |
James Hoxie |
University of Pennsylvania |
Structure/Function studies of CD4-independent HIV envelope glycoproteins |
| Sept. 25, 2001 |
Barney Graham, M.D., Ph.D. |
Vaccine Research Center |
Pathogenesis of respiratory syncytial virus: Implications for vaccine development |
| June 19, 2001 |
Bernard Moss, M.D., Ph.D. |
NIAID |
Molecular and Cellular Biology of Vaccinia Virus: Implications for use as a Vaccine Vector |
| June 12, 2001 |
Robinson James, M.D. |
Tulane University Health Sciences Center |
Antibodies Recognizing CD4-induced Epitopes of HIV-1 gp120 |
| June 5, 2001 |
Larry Arthur, Ph.D. |
NCI |
Inactivated virions; use as immunogens in vaccines and as in vitro reagents |
| May 29, 2001 |
Stephen E. Straus, M.D. |
NCCAM |
Development and testing of vaccines for genital herpes |
| May 22, 2001 |
Jay Berzofsky, M.D. |
NIH/NCI |
Approaches to design improved engineered vaccines for HIV |
| May 15, 2001 |
Joseph Sodroski, M.D. |
Department of Pathology, Harvard |
Immune evasion by HIV-1 |
| May 8, 2001 |
Larry Corey |
Fred Hutchinson Cancer Research Center |
Comparative trials of new vaccines: What happens after the initial results? |
| Apr. 24, 2001 |
Anthony Fauci, M.D. |
NIAID |
Host factors in HIV disease: Implications for therapeutic strategies |
| Apr. 17, 2001 |
John Moore, Ph.D. |
Cornell University |
Studies on HIV-1 envelope glycoprotein vaccine antigens and entry inhibitors |
| Apr. 10, 2001 |
George Lewis, PH.D. |
Institute of Human Virology |
Form and function of anti-viral beta-chemokines synthesized by diverse T cell subsets |
| Mar. 20, 2001 |
Malcolm Martin, M.D. |
Molecular Microbiology, NIAID |
The use of highly pathogenic SIV/HIV chimeric viruses for studies of immunodeficiency |
| Mar. 13, 2001 |
Dana H. Gabuzda, M.D. |
Dana-Farber Cancer Institute |
Role of HIV-1 envelope glycoproteins in neurotropism and viral pathogenesis |
| Feb. 27, 2001 |
William Paul, M.D. |
Laboratory of Immunology, NIAID |
Allelic bias in IL-4 expression: Mechanisms and significance |
| Feb. 20, 2001 |
Dennis R. Burton, Ph.D. |
Scripps Research Institute |
The anti-viral activities of antibodies in vitro and in vivo: rules and mechanisms |
| Feb. 13, 2001 |
Edward Berger, Ph.D. |
Laboratory of Viral Diseases, NIAID |
HIV Env/Receptor Interactions: Mechanisms and Opportunities |
| Jan. 30, 2001 |
Norman Letvin, M.D. |
Beth Israel Deaconess Medical Center |
Vaccine-induced CTL & control of AIDS Virus replication |
| Jan. 23, 2001 |
Gary Nabel, M.D., Ph.D. |
Vaccine Research Center, NIAID |
Progress and Challenges for AIDS Vaccine Development |